Body mass index (BMI) may be a prognostic factor for gastric cancer with peritoneal dissemination

Table 1 Clinical pathological data for gastric cancer patients with different BMI groups

Clinical pathological data		Fewer than 18.5 (n = 167 cases)		Between 18.5–23 (n = 232 cases)		Greater than 23 (n = 119 cases)		p value
Clinical pathological data		Cases	%	Cases	%	Cases	%
Age (years)	Mean	52.6		52.9		53.3		–
Age (years)	Range	20–85		19–85		29–84
Sex	Male	95	56.9	122	52.6	72	60.5
Sex	Female	72	43.1	110	47.4	47	39.5	0.347
Tumor location	Gastric cardia	40	24.0	47	20.3	31	26.1
	Middle	26	15.6	47	20.3	32	26.9
	Antrum	63	37.7	92	39.7	36	30.3
	Total stomach	38	22.8	46	19.8	20	16.8	0.181
Surgery	Gastrectomy	90	53.9	165	71.1	75	63.0
Surgery	No gastrectomy	77	46.1	67	28.9	44	37.0	0.002
Tumor size	<5 cm	50	29.9	91	39.2	47	39.5
	≥5 and <10 cm	83	49.7	104	44.8	56	47.1
	≥10 cm	34	20.4	37	15.9	16	13.4	0.249
Serum CEA level	<5 ng/ml	104	67.5	165	73.7	80	70.8
Serum CEA level	≥5 ng/ml	50	32.5	59	26.3	33	29.2	0.433
CA19-9 level	<35 U/ml	91	59.9	151	69.3	72	63.7
CA19-9 level	≥35U/ml	61	40.1	67	30.7	41	36.3	0.166
Seeding grade^a	P1	28	16.8	66	28.4	42	35.3
	P2	44	26.3	72	31.0	33	27.7
	P3	95	56.9	94	40.5	44	37.0	0.001
Multi-site metastasis	Without	97	58.1	181	78.0	81	68.1
Multi-site metastasis	With	70	41.9	51	22.0	38	31.9	< 0.001
Chemotherapy	Without	77	46.1	68	29.3	36	30.3
Chemotherapy	With	90	53.9	164	70.7	83	69.7	0.001

^aPeritoneal dissemination grade was divided into P1, P2, and P3 groups under the standard of first English version of Japanese classification of gastric carcinoma

ISSN: 1477-7819